Driving Re-Investment in R&D and Responsible Antibiotic Use

Developing new economic models to incentivise antibiotic discovery and development activities while safeguarding the efficacy of antibiotics by researching and advocating their appropriate use.

Principal Investigator: Elias Mossialos
Research Officer:
Chantal Morel
Start Date: 01 October 2014
End Date: 31 December 2017
Region: Europe/North America
Keywords: antibiotic resistance, antibiotic development, antibiotic incentives, market entry rewards

DRIVE-AB (Driving reinvestment in research and development and responsible antibiotic use) is a project exploring new business models intended to re-ignite R&D in novel antibiotics while also helping improve conservation. It seeks a system-wide detangling of supply- and demand-related incentives to ensure improved antibiotic effectiveness over the long-term.

LSE Health is an academic partner of the DRIVE-AB research project, under the Innovative Medicines Initiative’s New Drugs for Bad Bugs (ND4BB) program.

DRIVE-AB is a multi-stakeholder consortium tasked with developing innovative strategies for encouraging development of new antibiotics in a way that is equitable and sustainable.

The consortium is made up of 16 public and 7 private partners from 12 countries and is funded by the Innovative Medicines Initiative, a joint undertaking between the European Union and the European Pharmaceutical Industry Association. 

Fostering development of new antibiotics is a critical component in the global battle against antimicrobial resistance because there are few drugs currently in development that could replace the increasingly in-effective antibiotics we rely on every day to treat serious infections.

LSE Health provides expertise in the design of economic incentives that can be used to guide, support and reward developers of new antibiotics. In particular, LSE Health has been collaborating with policy makers and industry representatives to create a market entry reward that can be offered to developers who successfully make a valuable antibiotic approved for use in clinical settings.


DRIVE-AB’s final report and recommendations, along with LSE Health's work on market entry rewards, are expected to be released in early 2018.

To read more about the project's findings and outputs, visit the DRIVE-AB project website here.


Check back later for our latest Twitter updates.

Contact us


LSE Health, Cowdray House, London School of Economics and Political Science, Houghton Street, London WC2A 2AE

Follow us